• Je něco špatně v tomto záznamu ?

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

G. Salles, E. Bachy, L. Smolej, M. Simkovic, L. Baseggio, A. Panovska, H. Besson, N. Healy, J. Garside, W. Iraqi, J. Diels, C. Pick-Lauer, M. Spacek, R. Urbanova, D. Lysak, R. Hermans, J. Lundbom, E. Callet-Bauchu, M. Doubek,

. 2019 ; 98 (12) : 2749-2760. [pub] 20191119

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044454
E-zdroje Online Plný text

NLK ProQuest Central od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-03-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem

Odkazy

PubMed 31745601
DOI 10.1007/s00277-019-03830-8
Knihovny.cz E-zdroje

After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards model, adjusted for differences in baseline characteristics. Rituximab-containing regimens were often prescribed in clinical practice. The most frequently prescribed regimens were fludarabine + cyclophosphamide + rituximab (FCR, 29.3%), bendamustine + rituximab (BR, 17.7%), and other rituximab-containing regimens (22.0%) in the treatment-naïve setting (n = 604), other non-FCR/BR rituximab-containing regimens (38.7%) and non-rituximab-containing regimens (28.5%) in the relapsed/refractory setting (n = 945). Adjusted HRs (95% CI) for progression-free survival (PFS) and overall survival (OS), respectively, with ibrutinib versus real-world regimens were 0.23 (0.14-0.37; p < 0.0001) and 0.40 (0.22-0.76; p = 0.0048) in the treatment-naïve setting, and 0.21 (0.16-0.27; p < 0.0001) and 0.29 (0.21-0.41; p < 0.0001) in the relapsed/refractory setting. When comparing real-world use of ibrutinib (n = 53) versus other real-world regimens in relapsed/refractory CLL (objective 3), adjusted HRs (95% CI) were 0.37 (0.22-0.63; p = 0.0003) for PFS and 0.53 (0.27-1.03; p < 0.0624) for OS. This adjusted analysis, based on nonrandomized patient data, suggests ibrutinib to be more effective than other commonly used regimens for CLL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044454
003      
CZ-PrNML
005      
20200113080812.0
007      
ta
008      
200109s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-019-03830-8 $2 doi
035    __
$a (PubMed)31745601
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Salles, Gilles $u Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard, INSERM 1052, Pierre Bénite, France. gilles.salles@chu-lyon.fr.
245    10
$a Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia / $c G. Salles, E. Bachy, L. Smolej, M. Simkovic, L. Baseggio, A. Panovska, H. Besson, N. Healy, J. Garside, W. Iraqi, J. Diels, C. Pick-Lauer, M. Spacek, R. Urbanova, D. Lysak, R. Hermans, J. Lundbom, E. Callet-Bauchu, M. Doubek,
520    9_
$a After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards model, adjusted for differences in baseline characteristics. Rituximab-containing regimens were often prescribed in clinical practice. The most frequently prescribed regimens were fludarabine + cyclophosphamide + rituximab (FCR, 29.3%), bendamustine + rituximab (BR, 17.7%), and other rituximab-containing regimens (22.0%) in the treatment-naïve setting (n = 604), other non-FCR/BR rituximab-containing regimens (38.7%) and non-rituximab-containing regimens (28.5%) in the relapsed/refractory setting (n = 945). Adjusted HRs (95% CI) for progression-free survival (PFS) and overall survival (OS), respectively, with ibrutinib versus real-world regimens were 0.23 (0.14-0.37; p < 0.0001) and 0.40 (0.22-0.76; p = 0.0048) in the treatment-naïve setting, and 0.21 (0.16-0.27; p < 0.0001) and 0.29 (0.21-0.41; p < 0.0001) in the relapsed/refractory setting. When comparing real-world use of ibrutinib (n = 53) versus other real-world regimens in relapsed/refractory CLL (objective 3), adjusted HRs (95% CI) were 0.37 (0.22-0.63; p = 0.0003) for PFS and 0.53 (0.27-1.03; p < 0.0624) for OS. This adjusted analysis, based on nonrandomized patient data, suggests ibrutinib to be more effective than other commonly used regimens for CLL.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a bendamustin hydrochlorid $x aplikace a dávkování $7 D000069461
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    12
$a databáze faktografické $7 D016208
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x mortalita $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyrazoly $x aplikace a dávkování $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $7 D011743
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a míra přežití $7 D015996
650    _2
$a vidarabin $x aplikace a dávkování $x analogy a deriváty $7 D014740
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bachy, Emmanuel $u Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard, INSERM 1052, Pierre Bénite, France.
700    1_
$a Smolej, Lukas $u 4th Department of Internal Medicine, Hematology, University Hospital and Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.
700    1_
$a Simkovic, Martin $u 4th Department of Internal Medicine, Hematology, University Hospital and Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.
700    1_
$a Baseggio, Lucile $u Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard, INSERM 1052, Pierre Bénite, France.
700    1_
$a Panovska, Anna $u Department of Internal Medicine, Hematology and Oncology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Besson, Hervé $u , 's-Hertogenbosch, The Netherlands.
700    1_
$a Healy, Nollaig $u Janssen Sciences, Dublin, Ireland.
700    1_
$a Garside, Jamie $u Janssen-Cilag Limited, High Wycombe, UK.
700    1_
$a Iraqi, Wafae $u Janssen Pharmaceuticals, Paris, France.
700    1_
$a Diels, Joris $u Janssen Pharmaceutica NV, Beerse, Belgium.
700    1_
$a Pick-Lauer, Corinna $u Janssen-Cilag GmbH, Neuss, Germany.
700    1_
$a Spacek, Martin $u 1st Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Urbanova, Renata $u University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Lysak, Daniel $u University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Hermans, Ruben $u IQVIA Real-World Insight Solutions, London, UK.
700    1_
$a Lundbom, Jessica $u IQVIA Real-World Insight Solutions, London, UK.
700    1_
$a Callet-Bauchu, Evelyne $u Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard, INSERM 1052, Pierre Bénite, France.
700    1_
$a Doubek, Michael $u Department of Internal Medicine, Hematology and Oncology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic. CEITEC, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 98, č. 12 (2019), s. 2749-2760
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31745601 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081144 $b ABA008
999    __
$a ok $b bmc $g 1482723 $s 1083127
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 98 $c 12 $d 2749-2760 $e 20191119 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace